Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A case report of male breast cancer in a very young patient: what is changing?
Madeira M, Mattar A, Passos RJ, Mora CD, Mamede LH, Kishino VH, Torres TZ, de Sá AF, dos Santos RE, Gebrim LH. Madeira M, et al. Among authors: mattar a. World J Surg Oncol. 2011 Feb 3;9:16. doi: 10.1186/1477-7819-9-16. World J Surg Oncol. 2011. PMID: 21291532 Free PMC article.
Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer.
Madeira M, Mattar A, Logullo AF, Soares FA, Gebrim LH. Madeira M, et al. Among authors: mattar a. BMC Cancer. 2013 Sep 18;13:425. doi: 10.1186/1471-2407-13-425. BMC Cancer. 2013. PMID: 24047421 Free PMC article. Clinical Trial.
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Tan AR, Im SA, Mattar A, Colomer R, Stroyakovskii D, Nowecki Z, De Laurentiis M, Pierga JY, Jung KH, Schem C, Hogea A, Badovinac Crnjevic T, Heeson S, Shivhare M, Kirschbrown WP, Restuccia E, Jackisch C; FeDeriCa study group. Tan AR, et al. Among authors: mattar a. Lancet Oncol. 2021 Jan;22(1):85-97. doi: 10.1016/S1470-2045(20)30536-2. Epub 2020 Dec 21. Lancet Oncol. 2021. PMID: 33357420 Clinical Trial.
Management of early-stage triple-negative breast cancer: recommendations of a panel of experts from the Brazilian Society of Mastology.
Freitas-Junior R, de Oliveira VM, Frasson AL, Cavalcante FP, Mansani FP, Mattar A, Zerwes FP, de Oliveira Freitas AM, de Souza ABA, Damin AP, Dos Santos AMR, Ruiz CA, de Lucena CÊM, Millen EC, Bagnoli F, Andrade F, Rodrigues FLB, Facina G, Novita G, Pedrini JL, Guará JP, Soares LR, de Nigro Corpa MV, Passos M, de Lucena Ferreira NCF, Freitas NMA, Machado RHS, da Cunha Amaral RK, Reinert T, Budel VM. Freitas-Junior R, et al. Among authors: mattar a. BMC Cancer. 2022 Nov 22;22(1):1201. doi: 10.1186/s12885-022-10250-x. BMC Cancer. 2022. PMID: 36419031 Free PMC article.
Real-world evidence of neoadjuvant chemotherapy for breast cancer treatment in a Brazilian multicenter cohort: Correlation of pathological complete response with overall survival.
Antonini M, Mattar A, Bauk Richter FG, Pannain GD, Teixeira MD, Amorim AG, Ferraro O, Guedes Lopes RC, Gebrim LH, Real JM. Antonini M, et al. Among authors: mattar a. Breast. 2023 Dec;72:103577. doi: 10.1016/j.breast.2023.103577. Epub 2023 Sep 14. Breast. 2023. PMID: 37722319 Free PMC article.
144 results